Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

Hepatology

Volumn 29, Issue 6, 1999, Pages 1863-1869

  Tsiang, M ^a   Rooney, J F ^a   Toole, J J ^a   Gibbs, C S ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KINETICS; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

EID: 0033029334     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510290626     Document Type: Article

References (40)

1. 1 Lee WM. Hepatitis B virus infection. N Engl J Med 1997 ; 337: 1733–1745. MEDLINE
2. 2 Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995 ; 333: 1657–1661. MEDLINE
3. 3 Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′‐dideoxy‐3′‐thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991 ; 88: 8495–8499. MEDLINE
4. 4 Lai CL, Chien R‐N, Leung NWY, Chang T‐T, Guan R, Tai D‐I, Ng K‐Y, et al. A one‐year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998 ; 339: 61–68. MEDLINE
5. 5 Leung NWY, Lai CL, Liaw YF, Chang TT, Guan R, Tai DI, Ng KY, et al. Lamivudine (100 mg od) for 1 year significantly improves necro‐inflammatory activity and reduces progression in fibrosis stage: results of a placebo‐controlled multicentre study in Asia of lamivudine for chronic hepatitis B infection [Abstract]. Hepatology 1997 ; 26 (Suppl 4): 357A.
6. 6 Tanikawa K, Hayashi N, Ichida F, Lino S, Kumada H, Ogawa N, Okida K, et al. A placebo‐controlled phase III study of lamivudine in Japanese patients with chronic hepatitis B infection [Abstract]. Hepatology 1997 ; 26 (Suppl 4): 259A.
7. 7 Main J, Brow JL, Howells C, Galassini R, Crossey M, Karayiannis P, Georgiou P, et al. A double blind, placebo‐controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996 ; 3: 211–215. MEDLINE
8. 8 Gilson RJ, Chopra K, Murray‐Lyon IM, Newell AM, Nelson MR, Tedder RS, Toole JJ, et al. A placebo‐controlled phase I/II study of adefovir dipivoxil (bis‐POM PMEA) in patients with chronic hepatitis B infection [Abstract]. Hepatology 1996 ; 24 (Suppl 4): 281A.
9. 9 Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, et al. The safety and efficacy of adefovir dipivoxil, a novel anti‐human immunodeficiency virus (HIV) therapy, in HIV‐infected adults: a randomized, double‐blind, placebo‐controlled trial. J Infect Dis 1997 ; 176: 1517–1523. MEDLINE
10. 10 Jeffers L, Heathcote E, Wright T, Carithers R, di Bisceglie A, Perillo R, Rustgi V, et al. A phase II dose‐ranging, placebo‐controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection [Abstract]. Antiviral Res 1998 ; 37: A197.
11. 11 Bloomer J, Chan R, Sherman M, Ingraham P, DeHertogh D. A preliminary study of lobucavir for chronic hepatitis B [Abstract]. Hepatology 1997 ; 26 (Suppl 4): 428A.
12. 12 Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS‐200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997 ; 41: 1444–1448. MEDLINE
13. 13 Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV‐1 infection. Nature 1995 ; 373: 123–126. MEDLINE
14. 14 Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995 ; 373: 117–122. MEDLINE
15. 15 Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV‐1 dynamics in vivo: virion clearance rate, infected cell life‐span, and viral generation time. Science 1996 ; 271: 1582–1586. MEDLINE
16. 16 Nowak MA, Bangham CRM. Population dynamics of immune responses to persistent viruses. Science 1996 ; 272: 74–79. MEDLINE
17. 17 Herz AVM, Bonhoeffer S, Anderson RM, May RM, Nowak MA. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Proc Natl Acad Sci U S A 1996 ; 93: 7247–7251. MEDLINE
18. 18 Bonhoeffer S, Coffin JM, Nowak MA. Human immunodeficiency virus drug therapy and virus load. J Virol 1997 ; 71: 3275–3278. MEDLINE
19. 19 Nowak MA, Lloyd A, Vasquez GM, Wiltrout TA, Wahl LM, Bischofberger N, Williams J, et al. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol 1997 ; 71: 7518–7525. MEDLINE
20. 20 Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996 ; 93: 4398–4402. MEDLINE
21. 21 Payne RJH, Nowak MA, Blumberg BS. The dynamics of hepatitis B virus infection. Proc Natl Acad Sci U S A 1996 ; 93: 6542–6546. MEDLINE
22. 22 Zeuzem S, de Man RA, Honkoop P, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997 ; 27: 431–436. MEDLINE
23. 23 Bonhoeffer S, May RM, Shaw GM, Nowak MA. Viral dynamics and drug therapy. Proc Natl Acad Sci U S A 1997 ; 94: 6971–6976. MEDLINE
24. 24 Zeuzem S, Schmidt JM, Lee J‐H, Ruster B, Roth K. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996 ; 23: 366–371. MEDLINE
25. 25 Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997 ; 26: 226–231. MEDLINE
26. 26 Zeuzem S, Schmidt JM, Lee J‐H, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998 ; 28: 245–252. MEDLINE
27. 27 Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon‐α therapy. Science 1998 ; 282: 103–107. MEDLINE
28. 28 De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad‐spectrum anti‐DNA virus agent. Nature 1986 ; 323: 464–467. MEDLINE
29. 29 De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holy A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987 ; 8: 261–272. MEDLINE
30. 30 Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, Holy A, et al. Phosphonylmethoxyethyl purine derivatives, a new class of anti‐human immunodeficiency virus agents. Antimicrob Agents Chemother 1988 ; 32: 1025–1030. MEDLINE
31. 31 De Clercq E. Antiviral activity spectrum and target of action of different classes of nucleoside analogues. Nucleosides Nucleotides 1994 ; 13: 1271–1295.
32. 32 Tsiang M, Dale B, Rooney J, Toole JJ, Gibbs CS. Dynamics of hepatitis B virus clearance from the serum of patients treated with adefovir dipivoxil for 12 weeks [Abstract]. Hepatology 1992 ; 28 (Suppl 4): 492A.
33. 33 Barditch‐Crovo P, Toole J, Hendrix CW, Cundy KC, Ebeling D, Jaffe HS, Lietman PS. Anti‐human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9‐[2‐(bis‐pivaloyl‐ oxymethyl)‐phosphonylmethoxyethyl]adenine) in HIV‐infected patients. J Infect Dis 1997 ; 176: 406–413. MEDLINE
34. 34 Cundy KC, Sue IL, Visor GC, Marshburn J, Nakamura C, Lee WA, Shaw JP. Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. J Pharm Sci 1997 ; 86: 1334–1338. MEDLINE
35. 35 Orito E, Mizokami M, Ina Y, Moriyama EN, Kameshima N, Yamamoto M, Gojobori T. Host‐independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proc Natl Acad Sci U S A 1989 ; 86: 7059–7062. MEDLINE
36. 36 Ni YH, Chang MH, Chen PJ, Lin HH, Hsu HY. Evolution of hepatitis C virus quasispecies in mothers and infants infected through mother‐to‐infant transmission. J Hepatol 1997 ; 26: 967–974. MEDLINE
37. 37 Bianchi L, Gudat F. Viral antigens in liver tissue and type of inflammation in hepatitis B. In: Bianchi L, Gerok W, Sickinger K, eds. Virus and the Liver. Lancaster, UK: MTP. 1980 ; 197–204.
38. 38 Mason WS. The problem of antiviral therapy for chronic hepadnavirus infections. J Hepatol 1993 ; 17: S137–S142. MEDLINE
39. 39 Mason WS, Cullen J, Saputelli J, Wu TT, Liu C, London WT, Lustbader E, et al. Characterization of the antiviral effects of 2′ carbodeoxy‐guanosine in ducks chronically infected with duck hepatitis B virus. Hepatology 1994 ; 19: 398–411. MEDLINE
40. 40 Jacyna MR, Thomas HC. Pathogenesis and treatment of chronic infection. In: Zuckerman AJ, Thomas HC, eds. Viral Hepatitis. New York: Churchill Livingstone. 1993 ; 185–205.